Health boards warned to consider costs before offering cancer drug
30th Nov 2005, 00:37 GMT
HEALTH authorities should not rush to prescribe Herceptin to patients with early breast cancer without careful consideration of the impact on their budgets and the cost-effectiveness of the drug, researchers said yesterday.
Health boards warned to consider costs before offering cancer drug related news:
- Trusts 'can't afford breast cancer drug' — the Mail online | Health
- Breast Cancer Drug Costs 'Could Double' Report Highlights Financial Burden of Using Herceptin — RedOrbit News - Health
- Cancer Drug Green Light — RedOrbit News - Health
- Novartis Warns Doctors of Misusing Cancer Drug — RedOrbit News - Health
- Cancer Drug No Fertility Treatment — Health News: CBSnews.com
- Drug-Cost Growth Tops Norm — RedOrbit News - Health
- Warnings over cost of cancer drug — the Mail online | Health news
- Novartis Warns About Breast Cancer Drug Use — NYNewsday.com Health and Science headlines
- Warning issued for breast cancer drug — MSNBC.com: Health
- Will Herceptin be effective for early breast cancer? — Medical News Today RSS/XML Feed
Latest news from Scotsman.com News - UK:
- Policing issues threaten Ulster power sharing
- Ms Dynamite recovering after crash
- Woman awarded £259,000 damages in drug rape case
- Art discovery to sell for £1m
- First new Channel Tunnel link train to depart in a year
- Artist won't take Iraq war lying down
- 'UK FBI' fails to hit asset target
- Man on trial for murder of OAP in 1994
- Bakri uses web to back terror
- New charge for bank customers